CO2018009604A2 - Compuesto heterocíclico - Google Patents
Compuesto heterocíclicoInfo
- Publication number
- CO2018009604A2 CO2018009604A2 CONC2018/0009604A CO2018009604A CO2018009604A2 CO 2018009604 A2 CO2018009604 A2 CO 2018009604A2 CO 2018009604 A CO2018009604 A CO 2018009604A CO 2018009604 A2 CO2018009604 A2 CO 2018009604A2
- Authority
- CO
- Colombia
- Prior art keywords
- pain
- disease
- present
- heterocyclic compound
- compound
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 208000002193 Pain Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 206010065390 Inflammatory pain Diseases 0.000 abstract 1
- 102100029814 Monoglyceride lipase Human genes 0.000 abstract 1
- 101710116393 Monoglyceride lipase Proteins 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 1
- 208000029028 brain injury Diseases 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 208000004296 neuralgia Diseases 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000000472 traumatic effect Effects 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
RESUMEN La presente invención proporciona un compuesto que tiene una acción inhibidora de MAGL, y útil como un agente para la profilaxis o tratamiento de enfermedades neurodegenerativas (por ejemplo, enfermedad de Alzheimer, enfermedad de Parkinson, enfermedad de Huntington, esclerosis lateral amiotrófica, lesión cerebral traumática, glaucoma, esclerosis múltiple, etc.), trastorno de ansiedad, dolores (por ejemplo, dolor inflamatorio, dolor canceroso, dolor neurogénico, etc.), epilepsia, depresión y similares. La presente invención se refiere a un compuesto representado por la fórmula (I): donde cada símbolo es como se define en la memoria descriptiva, o una de sus sales.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016071181 | 2016-03-31 | ||
| PCT/JP2017/014597 WO2017171100A1 (en) | 2016-03-31 | 2017-03-30 | Heterocyclic compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2018009604A2 true CO2018009604A2 (es) | 2018-12-14 |
Family
ID=58707980
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2018/0009604A CO2018009604A2 (es) | 2016-03-31 | 2018-09-13 | Compuesto heterocíclico |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US10323026B2 (es) |
| EP (1) | EP3436444B1 (es) |
| JP (1) | JP6788683B2 (es) |
| KR (1) | KR102388440B1 (es) |
| CN (1) | CN109715613B (es) |
| AR (1) | AR108012A1 (es) |
| AU (1) | AU2017245125B2 (es) |
| BR (1) | BR112018068538B1 (es) |
| CA (1) | CA3019298C (es) |
| CL (1) | CL2018002777A1 (es) |
| CO (1) | CO2018009604A2 (es) |
| DK (1) | DK3436444T3 (es) |
| EA (1) | EA036637B1 (es) |
| EC (1) | ECSP18081909A (es) |
| ES (1) | ES2804580T3 (es) |
| IL (1) | IL261488B (es) |
| MX (1) | MX374833B (es) |
| MY (1) | MY194647A (es) |
| PE (1) | PE20190409A1 (es) |
| PH (1) | PH12018502101A1 (es) |
| PL (1) | PL3436444T3 (es) |
| SG (1) | SG11201807539UA (es) |
| TN (1) | TN2018000299A1 (es) |
| TW (1) | TWI738753B (es) |
| UA (1) | UA122435C2 (es) |
| UY (1) | UY37174A (es) |
| WO (1) | WO2017171100A1 (es) |
| ZA (1) | ZA201807249B (es) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201116559D0 (en) | 2011-09-26 | 2011-11-09 | Univ Leuven Kath | Novel viral replication inhibitors |
| JOP20160086B1 (ar) | 2015-05-08 | 2021-08-17 | 2 Katholieke Univ Leuven Ku Leuven Research And Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20160198B1 (ar) | 2015-09-16 | 2022-03-14 | Janssen Pharmaceuticals Inc | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JO3633B1 (ar) | 2015-09-16 | 2020-08-27 | Katholieke Univ Leuven Ku Leuven Research & Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| US10610520B2 (en) | 2016-03-31 | 2020-04-07 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| HUE054936T2 (hu) | 2016-03-31 | 2021-10-28 | Janssen Pharmaceuticals Inc | Helyettesített indol-származékok mint a dengue-vírus replikációjának inhibitorai |
| MX2018011788A (es) | 2016-03-31 | 2019-05-20 | Janssen Pharmaceuticals Inc | Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue. |
| AU2017240076A1 (en) | 2016-04-01 | 2018-08-09 | Janssen Pharmaceuticals, Inc. | Substituted indole compound derivatives as dengue viral replication inhibitors |
| JOP20170069B1 (ar) | 2016-04-01 | 2021-08-17 | 1 Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20190107A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| JOP20180025B1 (ar) | 2017-03-31 | 2021-08-17 | Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20180026A1 (ar) | 2017-03-31 | 2019-01-30 | Univ Leuven Kath | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| CN110753682B (zh) | 2017-05-22 | 2023-06-30 | 杨森制药公司 | 作为登革热病毒复制抑制剂的经取代的吲哚啉衍生物 |
| ES2929667T3 (es) | 2017-05-22 | 2022-11-30 | Janssen Pharmaceuticals Inc | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue |
| AU2018323459A1 (en) | 2017-08-29 | 2020-02-20 | H. Lundbeck A/S. | Spirocycle compounds and methods of making and using same |
| EP3689879B1 (en) | 2017-09-29 | 2025-02-12 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| AR114136A1 (es) | 2017-10-10 | 2020-07-29 | Hoffmann La Roche | Compuestos heterocíclicos |
| EP3717477B1 (en) * | 2017-11-28 | 2022-07-20 | F. Hoffmann-La Roche AG | New heterocyclic compounds |
| TW201930300A (zh) * | 2017-12-15 | 2019-08-01 | 瑞士商赫孚孟拉羅股份公司 | 新雜環化合物 |
| EP3737680A1 (en) | 2018-01-08 | 2020-11-18 | F. Hoffmann-La Roche AG | Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors |
| RS65912B1 (sr) | 2018-08-13 | 2024-10-31 | Hoffmann La Roche | Nova heterociklična jedinjenja kao inhibitori monoacilglicerol lipaze |
| BR112020025642A2 (pt) * | 2018-08-13 | 2021-03-23 | F. Hoffmann-La Roche Ag | compostos heterocíclicos como inibidores da monoacilglicerol lipase |
| JP7609854B2 (ja) | 2019-09-12 | 2025-01-07 | エフ． ホフマン－ラ ロシュ アーゲー | Ｍａｇｌ阻害剤としての４，４ａ，５，７，８，８ａ－ヘキサピリド［４，３－ｂ］［１，４］オキサジン－３－オン化合物 |
| JOP20220180A1 (ar) * | 2020-02-10 | 2023-01-30 | Janssen Pharmaceutica Nv | مُعدلات ليباز أُحادِيُّ الجلِيسِريد |
| JP7729831B2 (ja) * | 2020-03-26 | 2025-08-26 | ヤンセン ファーマシューティカ エヌ．ベー． | モノアシルグリセロールリパーゼ調節因子としてのアミノシクロブタン |
| BR112022019155A2 (pt) | 2020-03-26 | 2022-12-06 | Janssen Pharmaceutica Nv | Aril piperidinas como moduladores da monoacilglicerol lipase |
| AU2021241888A1 (en) * | 2020-03-26 | 2022-09-29 | Janssen Pharmaceutica Nv | Azaspirocycles as monoacylglycerol lipase modulators |
| CN115989228A (zh) | 2020-09-03 | 2023-04-18 | 豪夫迈·罗氏有限公司 | 杂环化合物 |
| UY39516A (es) | 2020-11-13 | 2022-05-31 | H Lundbeck As | Composición para el tratamiento de una enfermedad vascular, composición para la prevención de una enfermedad vascular, composición para el tratamiento de la hipertensión, y composición para la prevención de la hipertensión |
| KR20240005747A (ko) | 2021-05-08 | 2024-01-12 | 얀센 파마슈티카 엔브이 | 치환된 스피로 유도체 |
| US11974987B2 (en) | 2021-08-09 | 2024-05-07 | Janssen Pharmaceutica Nv | Monoacylglycerol lipase modulators for use in autism spectrum disorders |
| WO2023130023A1 (en) | 2021-12-29 | 2023-07-06 | Psy Therapeutics, Inc. | Inhibiting monoacylglycerol lipase (magl) |
| CN115925699B (zh) * | 2022-02-25 | 2023-10-03 | 南京知和医药科技有限公司 | 具有镇痛活性的稠环化合物及其制备方法与用途 |
| CN119137114A (zh) | 2022-05-04 | 2024-12-13 | H.隆德贝克有限公司 | 作为单酰基甘油脂肪酶抑制剂的(s)-1-(哒嗪-3-基氨基甲酰基)-6-氮杂螺[2.5]辛烷-6-甲酸1,1,1,3,3,3-六氟丙-2-酯的结晶形式 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE469875T1 (de) * | 2002-03-13 | 2010-06-15 | Schering Corp | Nk1-antagonisten |
| TW200902007A (en) * | 2007-05-25 | 2009-01-16 | Astrazeneca Ab | Spirocyclopropyl piperidine derivatives |
| TWI495637B (zh) | 2009-04-22 | 2015-08-11 | Janssen Pharmaceutica Nv | 用作單醯基甘油脂肪酶抑制劑之雜芳族及芳族六氫吡基吖丁啶基醯胺（一） |
| KR20120005517A (ko) | 2009-04-22 | 2012-01-16 | 얀센 파마슈티카 엔.브이. | 모노아실글리세롤 리파제 억제제로서의 헤테로방향족 및 방향족 피페라지닐 아제티디닐 아미드 |
| US8415341B2 (en) | 2009-04-22 | 2013-04-09 | Janssen Pharmaceutica, Nv | Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors |
| AR076381A1 (es) | 2009-04-22 | 2011-06-08 | Janssen Pharmaceutica Nv | Azetidinil diamidas como inhibidores de monoacilglicerol lipasa |
| EP2486034A1 (en) * | 2009-10-07 | 2012-08-15 | Bristol-Myers Squibb Company | Spirocyclic compounds as modulators of chemokine receptor activity |
| WO2012030907A1 (en) | 2010-09-03 | 2012-03-08 | Janssen Pharmaceutica Nv | Di-azetidinyl diamide as monoacylglycerol lipase inhibitors |
| KR20140001206A (ko) | 2010-09-27 | 2014-01-06 | 얀센 파마슈티카 엔.브이. | 모노아실글리세롤 리파아제 억제제로서의 옥소피페라진-아제티딘 아미드 및 옥소다이아제핀-아제티딘 아미드 |
| US8513423B2 (en) | 2010-10-22 | 2013-08-20 | Janssen Pharmaceutica, Nv | Piperidin-4-yl-azetidine diamides as monoacylglycerol lipase inhibitors |
| CA2815350A1 (en) * | 2010-10-22 | 2012-04-26 | Janssen Pharmaceutica Nv | Piperidin-4-yl-azetidine diamides as monoacylglycerol lipase inhibitors |
| CN103957916A (zh) | 2011-09-30 | 2014-07-30 | 詹森药业有限公司 | 用于治疗代谢疾病和相关失调的单酰甘油脂肪酶抑制剂 |
| MX2014003883A (es) | 2011-09-30 | 2014-08-27 | Janssen Pharmaceutica Nv | Inhibidores de monoacilglicerol lipasa para el tratamiento de enfermedades metabolicas y transtornos relacionados. |
| EA028085B1 (ru) * | 2012-01-06 | 2017-10-31 | Эбайд Терапьютикс, Инк. | Карбаматные соединения и их применение |
| EP3087067B1 (en) | 2013-12-26 | 2018-10-24 | Takeda Pharmaceutical Company Limited | 4-(piperrazin-1-yl)-pyrrolidin-2-one compounds as monoacylglycerol lipase (magl) inhibitors |
| US10314841B2 (en) * | 2014-01-09 | 2019-06-11 | Merck Patent Gmbh | Substituted pyrazoles as IRAK inhibitors |
| WO2016158956A1 (ja) | 2015-03-30 | 2016-10-06 | 武田薬品工業株式会社 | 複素環化合物 |
-
2017
- 2017-03-30 EP EP17723531.4A patent/EP3436444B1/en active Active
- 2017-03-30 JP JP2018549603A patent/JP6788683B2/ja active Active
- 2017-03-30 AR ARP170100789A patent/AR108012A1/es active IP Right Grant
- 2017-03-30 CA CA3019298A patent/CA3019298C/en active Active
- 2017-03-30 KR KR1020187030584A patent/KR102388440B1/ko active Active
- 2017-03-30 WO PCT/JP2017/014597 patent/WO2017171100A1/en not_active Ceased
- 2017-03-30 DK DK17723531.4T patent/DK3436444T3/da active
- 2017-03-30 BR BR112018068538-0A patent/BR112018068538B1/pt active IP Right Grant
- 2017-03-30 UA UAA201810731A patent/UA122435C2/uk unknown
- 2017-03-30 TW TW106110783A patent/TWI738753B/zh active
- 2017-03-30 EA EA201892215A patent/EA036637B1/ru not_active IP Right Cessation
- 2017-03-30 AU AU2017245125A patent/AU2017245125B2/en active Active
- 2017-03-30 SG SG11201807539UA patent/SG11201807539UA/en unknown
- 2017-03-30 PE PE2018001848A patent/PE20190409A1/es unknown
- 2017-03-30 TN TNP/2018/000299A patent/TN2018000299A1/en unknown
- 2017-03-30 ES ES17723531T patent/ES2804580T3/es active Active
- 2017-03-30 MX MX2018011729A patent/MX374833B/es active IP Right Grant
- 2017-03-30 MY MYPI2018703541A patent/MY194647A/en unknown
- 2017-03-30 CN CN201780032516.6A patent/CN109715613B/zh active Active
- 2017-03-30 UY UY0001037174A patent/UY37174A/es not_active Application Discontinuation
- 2017-03-30 US US15/474,192 patent/US10323026B2/en active Active
- 2017-03-30 PL PL17723531T patent/PL3436444T3/pl unknown
-
2018
- 2018-08-30 IL IL261488A patent/IL261488B/en active IP Right Grant
- 2018-09-13 CO CONC2018/0009604A patent/CO2018009604A2/es unknown
- 2018-09-28 PH PH12018502101A patent/PH12018502101A1/en unknown
- 2018-09-28 CL CL2018002777A patent/CL2018002777A1/es unknown
- 2018-10-30 EC ECSENADI201881909A patent/ECSP18081909A/es unknown
- 2018-10-30 ZA ZA2018/07249A patent/ZA201807249B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2018009604A2 (es) | Compuesto heterocíclico | |
| CO2020003932A2 (es) | Compuesto heterocíclico | |
| DOP2018000031A (es) | DERIVADOS DE 1,1,1-TRIFLUORO-3-HIDROXIPROPAN-2-IL CARBAMATO y DERIVADOS DE 1,1,1-TRIFLUORO-4-HIDROXIBUTAN-2-IL CARBAMATO COMO INHIBIDORES DE MAGL | |
| UY36071A (es) | Compuesto de ciclopropanamina y sus usos | |
| MX2022004102A (es) | Composiciones de oligonucleotidos y metodos de uso de las mismas. | |
| BR112015026660A2 (pt) | ligas metálicas aperfeiçoadas para dispositivos médicos | |
| DOP2018000204A (es) | Moduladores alostéricos de receptores de acetilcolina nicotínicos | |
| MX381069B (es) | Profármacos de carbidopa y l-dopa y métodos de uso. | |
| DOP2016000195A (es) | Compuestos | |
| MX2019000980A (es) | Compuestos y composiciones y usos de los mismos. | |
| BR112018069533A2 (pt) | tratamento de condições alérgicas oculares com ciclodextrinas | |
| BR112018010564A2 (pt) | composições farmacêuticas compreendendo levodopa amida e usos das mesmas | |
| MX2015017169A (es) | Compuestos heteroaromaticos y su uso como ligandos d1 de dopamina. | |
| WO2014160871A3 (en) | Methods and agents for treating alzheimer's disease | |
| MX391725B (es) | Compuestos y metodos para tratamiento de afecciones neurologicas y cardiovasculares. | |
| CL2019000534A1 (es) | Inhibidores de cinasa de cremallera de leucina dual (dlk) para el tratamiento de enfermedades. | |
| EA201691602A1 (ru) | Комбинация баклофена, акампросата и среднецепочечных триглицеридов для лечения неврологических расстройств | |
| AR112472A1 (es) | Forma de sales cristalinas de amida de levodopa y métodos para elaborarlas y usarlas | |
| MX2016007803A (es) | Composiciones de acidos grasos omega 3 para tratar enfermedades que implican daños al sistema nervioso. | |
| BR112016016098A2 (pt) | Compostos orgânicos | |
| EA201792076A1 (ru) | Методы и композиции для внутривенного введения фумаратов для лечения неврологических заболеваний | |
| AR120165A1 (es) | Composiciones de oligonucleótidos y métodos de uso de las mismas | |
| BR112019004864A2 (pt) | inibidores cetona de lisina gingipain | |
| UY35603A (es) | Compuesto heterocíclico |